Impact of hidradenitis suppurativa on work loss, indirect costs and income.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
accepted:
13
08
2018
pubmed:
19
8
2018
medline:
29
8
2020
entrez:
19
8
2018
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS), a chronic cutaneous disease, can negatively affect work life. This retrospective cohort study evaluates the indirect burden among employed patients with HS in the U.S.A. Newly diagnosed and general patients with HS, who were employees (age 18-64 years) from a large claims database (Q1 1999 to Q1 2015), were matched 1 : 5 to controls. Income growth and risk of leaving the workforce were assessed among the newly diagnosed HS and control cohorts in the 5-year study period. Income, work loss days and indirect costs (absenteeism and disability) were assessed among the general HS and control cohorts in the 1-year study period. Newly diagnosed (n = 1003, mean age 39·5 years, 66·3% female) and general patients with HS (n = 1204, mean age 39·9 years, 69·1% female) were matched to 5015 and 6020 controls, respectively. Newly diagnosed patients with HS had significantly slower income growth ($324 per year) and higher risk of leaving the workforce (adjusted hazard ratio 1·65, 95% confidence interval 1·45-1·88) compared with controls (all P < 0·05). General patients with HS had more total days of work loss (18·4 vs. 7·7), higher annual total indirect costs ($2925 vs. $1483) and lower annual income ($54 925 vs. $62 357) than controls (all P < 0·001). Patients with newly diagnosed HS and general patients with HS experienced a greater indirect burden than matched controls.
Sections du résumé
BACKGROUND
Hidradenitis suppurativa (HS), a chronic cutaneous disease, can negatively affect work life.
OBJECTIVES
This retrospective cohort study evaluates the indirect burden among employed patients with HS in the U.S.A.
METHODS
Newly diagnosed and general patients with HS, who were employees (age 18-64 years) from a large claims database (Q1 1999 to Q1 2015), were matched 1 : 5 to controls. Income growth and risk of leaving the workforce were assessed among the newly diagnosed HS and control cohorts in the 5-year study period. Income, work loss days and indirect costs (absenteeism and disability) were assessed among the general HS and control cohorts in the 1-year study period.
RESULTS
Newly diagnosed (n = 1003, mean age 39·5 years, 66·3% female) and general patients with HS (n = 1204, mean age 39·9 years, 69·1% female) were matched to 5015 and 6020 controls, respectively. Newly diagnosed patients with HS had significantly slower income growth ($324 per year) and higher risk of leaving the workforce (adjusted hazard ratio 1·65, 95% confidence interval 1·45-1·88) compared with controls (all P < 0·05). General patients with HS had more total days of work loss (18·4 vs. 7·7), higher annual total indirect costs ($2925 vs. $1483) and lower annual income ($54 925 vs. $62 357) than controls (all P < 0·001).
CONCLUSIONS
Patients with newly diagnosed HS and general patients with HS experienced a greater indirect burden than matched controls.
Identifiants
pubmed: 30120887
doi: 10.1111/bjd.17101
pmc: PMC7379487
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-154Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
N Engl J Med. 2012 Jan 12;366(2):158-64
pubmed: 22236226
J Am Acad Dermatol. 2013 Nov;69(5):819
pubmed: 24124817
N Engl J Med. 2016 Aug 4;375(5):422-34
pubmed: 27518661
J Eur Acad Dermatol Venereol. 2000 Sep;14(5):389-92
pubmed: 11305381
Acta Derm Venereol. 2010 May;90(3):264-8
pubmed: 20526543
Eur J Pharmacol. 2011 Dec 15;672(1-3):1-8
pubmed: 21930119
Semin Cutan Med Surg. 2014 Jun;33(3 Suppl):S57-9
pubmed: 25188460
JAMA Dermatol. 2014 Sep;150(9):937-44
pubmed: 24908260
Cutis. 2015 Dec;96(6 Suppl):7-12
pubmed: 27051885
J Am Acad Dermatol. 2007 Apr;56(4):621-3
pubmed: 17097366
Acta Derm Venereol. 2011 May;91(3):328-32
pubmed: 21394419
J Am Acad Dermatol. 2010 Apr;62(4):706-8, 708.e1
pubmed: 20227585
J Am Acad Dermatol. 2017 Jul;77(1):118-122
pubmed: 28285782
J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98
pubmed: 19682181
Dermatol Clin. 2016 Jan;34(1):7-16
pubmed: 26617352
JAMA Dermatol. 2017 Aug 1;153(8):760-764
pubmed: 28492923
J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3
pubmed: 19293006
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):467-473
pubmed: 29125658